share_log

Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors

Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors

Aeglea生物治療公司任命亨特·C·史密斯為董事會成員
PR Newswire ·  2021/11/16 20:25

AUSTIN, Texas, Nov. 16, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Hunter C. Smith to its board of directors. Mr. Smith currently serves as the chief financial officer of Rhythm Pharmaceuticals.

德克薩斯州奧斯汀2021年11月16日/美通社/--Aeglea BioTreateutics,Inc.(納斯達克市場代碼:AGLE)是一家臨牀階段的生物技術公司,開發新一代人類酶療法作為罕見代謝性疾病的創新解決方案,該公司今天宣佈任命亨特·C·史密斯為董事會成員。史密斯先生目前擔任Rhythm製藥公司的首席財務官。

"We are excited to welcome Hunter to our board of directors and to the Aeglea family," said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. "Hunter brings a wealth of experience as a biotech leader including corporate strategy, global commercial planning and product launches. His addition to our board will bring valuable experience and input as we further our mission to bring human enzyme therapies to people living with rare metabolic diseases."

Aeglea公司總裁兼首席執行官安東尼·奎因(Anthony Quinn)説:“我們很高興歡迎亨特加入我們的董事會和Aeglea大家庭。亨特作為生物技術領先者帶來了豐富的經驗,包括公司戰略、全球商業規劃和產品推出。他加入我們董事會將帶來寶貴的經驗和投入,因為我們將進一步履行我們的使命,將人類酶療法帶給患有罕見代謝性疾病的人。“

"I'm excited to be joining the board of Aeglea, particularly as the company is on the cusp of pivotal data from its trial for its Arginase 1 Deficiency program next month," said Mr. Smith. "I look forward to working with existing board members and the Aeglea team as they advance Aeglea toward becoming a commercial-stage company while continuing to realize the immense potential of its human enzyme therapy pipeline."

史密斯説:“我很高興能加入Aeglea的董事會,特別是因為該公司正處於下個月精氨酸酶1缺乏症試驗的關鍵數據的尖端。”我期待着與現有的董事會成員和Aeglea團隊合作,推動Aeglea公司成為一家商業階段的公司,同時繼續實現其人類酶療法流水線的巨大潛力。“

Mr. Smith's roles at biopharma companies include senior-level leadership, corporate strategy and financial oversight of commercial operations. Mr. Smith has served as the chief financial officer of Rhythm Pharmaceuticals since 2017 and served as interim chief executive officer from March to July 2020. Prior to joining Rhythm, Mr. Smith was vice president, finance and chief financial officer of Celgene Corporation's inflammation and immunology business unit where he provided financial and strategic leadership for the global launch of Otezla®. Prior to Celgene, Mr. Smith held roles of increasing responsibility at Bunge Limited. He holds an M.B.A in finance from NYU's Stern School of Business and a B.A. in history, with honors, from Northwestern University.

史密斯先生在生物製藥公司擔任的職務包括高級領導、公司戰略和商業運營的財務監督。史密斯自2017年以來一直擔任Rhythm PharmPharmticals的首席財務官,並於2020年3月至7月擔任臨時首席執行官。在加入Rhythm之前,Smith先生是Celgene Corporation炎症和免疫事業部的財務副總裁兼首席財務官,負責Otezla®全球發佈的財務和戰略領導工作。在加入Celgene之前,史密斯先生在Bunge Limited擔任的職務越來越多。他擁有哈佛大學的金融碩士學位。紐約大學的斯特恩商學院(Stern School Of Business),西北大學(Northwest University)歷史學學士,以優異成績畢業。

About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The company began dosing patients in a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria in June 2021. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.

關於Aeglea生物治療公司
Aeglea生物治療公司是一家臨牀階段的生物技術公司,它重新定義了人類酶療法的潛力,使治療選擇有限的罕見代謝性疾病患者受益。Aeglea的主要候選產品pegzilarginase正處於治療精氨酸酶1缺乏症的關鍵3期試驗,並已獲得罕見兒科疾病和突破性治療稱號。該公司於2021年6月開始在治療同型半胱氨酸尿症的1/2期臨牀試驗中給患者服用Agle-177。Agle-177還被授予罕見兒科疾病稱號。Aeglea有一個活躍的發現平臺,專注於設計人類酶的微小變化,以對患者及其家人的生活產生重大影響。欲瞭解更多信息,請訪問網址:http://aeglea.com.。

Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our ability to obtain regulatory approval for, and commercialize, pegzilarginase, recognize milestone and royalty payments from our agreement with Immedica, cash forecasts, the timing and success of our clinical trials and related data, the timing and expectations for regulatory submissions and approvals, timing and results of meetings with regulators, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, the expected impact of the COVID-19 pandemic on our operations and clinical trials, success in our collaborations, the potential addressable markets of our product candidates and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Annual Report on Form 10-Q for the quarter ended September 30, 2021 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

安全港/前瞻性陳述
本新聞稿包含符合“1995年美國私人證券訴訟改革法”安全港條款的“前瞻性”陳述。前瞻性陳述可以通過諸如“預期”、“打算”、“計劃”、“目標”、“尋求”、“相信”、“項目”、“估計”、“預期”、“戰略”、“未來”、“可能”、“可能”、“應該”、“將”以及對未來時期的類似提法來識別。這些陳述受到許多風險和不確定因素的影響,這些風險和不確定因素可能導致實際結果與我們預期的大不相同。這些前瞻性聲明包括,但不限於我們對培基精氨酸酶獲得監管部門批准並將其商業化的能力,從我們與伊梅達公司的協議中確認里程碑和特許權使用費支付的能力,現金預測,我們臨牀試驗及相關數據的時間和成功,監管機構提交和批准的時間和預期,與監管機構舉行會議的時間和結果,與我們的臨牀試驗和相關數據相關的宣佈和更新的時間,我們招募患者參加臨牀試驗的能力,新冠肺炎大流行對我們臨牀試驗的預期影響。我們候選產品的潛在潛在市場,以及我們的主導候選產品或其他候選產品的潛在治療益處和經濟價值。有關可能影響我們的業務及其財務業績的潛在風險因素的詳細信息,請參閲我們提交給美國證券交易委員會(美國證券交易委員會)的最新年度報告Form 10-Q(截至2021年9月30日的季度)以及提交給美國證券交易委員會的其他報告。我們沒有義務公開更新任何可能不時做出的前瞻性陳述,無論是書面的還是口頭的,無論是由於新的信息。, 未來的發展或其他方面。

SOURCE Aeglea BioTherapeutics, Inc.

來源:Aeglea BioTreeutics,Inc.

Related Links

相關鏈接

www.aegleabio.com

Www.aegleabio.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論